

MINOGUE MICHAEL R

Form 4

June 25, 2018

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MINOGUE MICHAEL R

(Last) (First) (Middle)

C/O ABIOMED, INC., 22  
CHERRY HILL DRIVE

(Street)

DANVERS, MA 01923

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
ABIOMED INC [ABMD]

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/21/2018

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)

Chairman, President, CEO

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------|---|---|--------------------------------------|---|--|---|---|
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018                              |   | M <sup>(5)</sup>                     | 105,000<br><sup>(5)</sup>   | A \$ 10.03   | 481,150   | D   |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018                              |   | S <sup>(6)</sup>                     | 2,400 <sup>(6)</sup>  | D \$<br>434.4738<br><sup>(7)</sup>   | 478,750   | D   |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018                              |   | S <sup>(6)</sup>                     | 7,984 <sup>(6)</sup>  | D \$<br>435.6334<br><sup>(8)</sup>   | 470,766   | D   |

Edgar Filing: MINOGUE MICHAEL R - Form 4

|                                       |            |                  |                       |   |                                |         |   |
|---------------------------------------|------------|------------------|-----------------------|---|--------------------------------|---------|---|
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 5,481 <sup>(6)</sup>  | D | \$<br>436.7592 <sup>(9)</sup>  | 465,285 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 8,009 <sup>(6)</sup>  | D | \$ 437.884 <sup>(10)</sup>     | 457,276 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 30,611 <sup>(6)</sup> | D | \$<br>438.6508 <sup>(11)</sup> | 426,655 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 24,497 <sup>(6)</sup> | D | \$<br>439.7387 <sup>(12)</sup> | 402,168 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 6,696 <sup>(6)</sup>  | D | \$<br>440.6038 <sup>(13)</sup> | 395,472 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 3,634 <sup>(6)</sup>  | D | \$<br>441.7512 <sup>(14)</sup> | 391,838 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 1,293 <sup>(6)</sup>  | D | \$<br>442.7477 <sup>(15)</sup> | 390,545 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 3,300 <sup>(6)</sup>  | D | \$<br>443.7724 <sup>(16)</sup> | 387,245 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 4,325 <sup>(6)</sup>  | D | \$<br>445.1681 <sup>(17)</sup> | 382,920 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 1,605 <sup>(6)</sup>  | D | \$<br>445.9237 <sup>(18)</sup> | 381,315 | D |
| Common<br>Stock<br>\$.01 par<br>value | 06/21/2018 | S <sup>(6)</sup> | 4,165 <sup>(6)</sup>  | D | \$<br>447.0059 <sup>(19)</sup> | 377,150 | D |
|                                       | 06/21/2018 | S <sup>(6)</sup> | 1,000 <sup>(6)</sup>  | D | \$ 450.06                      | 376,150 | D |

Common  
Stock  
\$.01 par  
value

Common  
Stock  
\$.01 par  
value

Common  
Stock  
\$.01 par  
value

Common  
Stock  
\$.01 par  
value

Common  
Stock  
\$.01 par  
value

Common  
Stock  
\$.01 par  
value

46,654

I

By Trust  
- A

73,745

I

By Trust  
- B

9,000

I

By Trust  
- C

655

I

By Trust  
- D

38,560

I

By Trust  
- E

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4, and<br>5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>Underlying Securities<br>(Instr. 3 and 4) |                            |
|---|---|---|---|---|---|--|--------------------|--|----------------------------|
|   |   |   |   | Code                                    | V (A) (D)   | Date Exercisable   | Expiration<br>Date | Title  | Amount<br>Number<br>Shares |
| Stock<br>Option<br>(right to<br>buy) <sup>(2)</sup> | \$ 10.03  | 06/21/2018                              |   | M <sup>(5)</sup>                        | 105,000<br><sup>(5)</sup>   | 06/03/2011 <sup>(1)</sup>                                      | 06/03/2020         | Common<br>Stock  | 105,                       |

|   |           |                           |            |                 |   |
|---|-----------|---------------------------|------------|-----------------|---|
| Stock<br>Option<br>(Right to<br>Buy) <sup>(2)</sup> | \$ 22.44  | 05/22/2013 <sup>(1)</sup> | 05/22/2022 | Common<br>Stock | 0 |
| Stock<br>Option<br>(Right to<br>Buy) <sup>(2)</sup> | \$ 23.15  | 05/14/2014 <sup>(1)</sup> | 05/14/2024 | Common<br>stock | 0 |
| Stock<br>Option<br>(right to<br>buy) <sup>(2)</sup> | \$ 21.55  | 05/14/2015 <sup>(3)</sup> | 05/14/2024 | Common<br>Stock | 0 |
| Stock<br>Option<br>(right to<br>buy) <sup>(2)</sup> | \$ 66.25  | 05/13/2016 <sup>(3)</sup> | 05/13/2025 | Common<br>Stock | 0 |
| Stock<br>Option<br>(right to<br>buy) <sup>(4)</sup> | \$ 99.62  | 05/24/2017 <sup>(3)</sup> | 05/24/2026 | Common<br>Stock | 0 |
| Stock<br>Option<br>(right to<br>buy) <sup>(4)</sup> | \$ 134.51 | 05/15/2018 <sup>(3)</sup> | 05/15/2027 | Common<br>Stock | 0 |
| Stock<br>Option<br>(right to<br>buy) <sup>(4)</sup> | \$ 381.97 | 05/16/2019 <sup>(3)</sup> | 05/16/2028 | Common<br>Stock | 0 |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                          |       |
|--|---------------|-----------|--------------------------|-------|
|  | Director      | 10% Owner | Officer                  | Other |
| MINOGUE MICHAEL R<br>C/O ABIOMED, INC.,<br>22 CHERRY HILL DRIVE<br>DANVERS, MA 01923 | X             |           | Chairman, President, CEO |       |

## Signatures

/s/ Stephen C. McEvoy (by power of attorney) 06/25/2018

<sup>\_\_</sup>Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- (2) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- (3) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- (5) Exercise of stock options pursuant to reporting owner's 10b5-1 plan.
- (6) Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- (7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$434.0900 and \$435.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$435.1400 and \$436.0400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (9) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$436.1800 and \$437.1700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (10) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$437.1900 and \$438.1600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (11) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$438.1700 and \$439.1400. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (12) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$439.1700 and \$440.1600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (13) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$440.1700 and \$441.0800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (14) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$441.1800 and \$442.1500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (15) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$442.3700 and \$442.9000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (16) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$443.4300 and \$444.0700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (17) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$444.5400 and \$445.5100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (18) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$445.6700 and \$446.5000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (19) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$446.8300 and \$447.2800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

## Edgar Filing: MINOGUE MICHAEL R - Form 4

request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.